Snap Chart
Global healthcare buyout deal activity moderated in the first half of 2026, with disclosed deal value falling below that of the first half of 2025, even as volume edged higher. The momentum characterizing the second half of 2025 waned as a wave of uncertainty—the AI-driven “SaaSpocalypse,” the Iran war, and redemption stress in the private credit market—weighed on activity.
Regionally, North America saw buyout value rise appreciably in the first half of 2026 compared to 2025, on volume that was broadly equivalent to a year ago. In Europe, volume remained mostly stable year over year, though disclosed value fell meaningfully. Asia-Pacific activity was roughly in line with the year-ago period.
Provider-related transaction value increased significantly in the first half of 2026, driven by multiple transactions spanning a range of subsectors, including both care delivery and healthcare IT/tech services, rather than reflecting one investment theme. The “SaaSpocalypse” muted healthcare IT deal activity, with volume in line with the first half of 2025 and value driven mainly by the Ensemble Health Partners transaction. Investors were cautious about bringing assets to the market given current valuation dynamics and showed appetite for areas with clear transformation theses, such as tech-enabled services.
Looking to the second half of 2026, ample dry powder and ongoing pressure to return capital to investors support continued deal activity. Creative deal structures, including take-privates, featured prominently in the first half of the year and may persist. As in the broader private equity landscape, revenue expansion and multiple arbitrage are no longer sufficient to propel returns. In an AI era where “12 is the new 5,” value creation and AI investment posture have become increasingly important considerations for winning investments.